Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rufinamide.

D Heaney1, M C Walker

  • 1Department of Clinical and Experimental Epilepsy, Institute of Neurology, UCL, and National Hospital for Neurology and Neurosurgery, London, UK.

Drugs of Today (Barcelona, Spain : 1998)
|August 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Unlocking seizure freedom: A European Delphi panel study on the clinical, humanistic, and economic value of seizure control in epilepsy.

Seizure·2026
Same author

Is a separate clinical pathway for first seizures justified? Appraisal of the first seizure pathway at a tertiary neuroscience centre.

Seizure·2020
Same author

CARTR Plus: the creation of an ART registry in Canada.

Human reproduction open·2020
Same author

Reactive oxygen species in status epilepticus.

Epilepsy & behavior : E&B·2019
Same author

Decreasing the risk of sudden unexpected death in epilepsy: structured communication of risk factors for premature mortality in people with epilepsy.

European journal of neurology·2018
Same author

A case of pure gelastic seizures due to hypothalamic hamartoma with a benign course.

Epilepsy & behavior case reports·2017
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Rufinamide demonstrates efficacy in epilepsy models and as adjunctive therapy for partial epilepsy and Lennox-Gastaut syndrome. Further trials are needed to confirm its advantages over existing antiepileptic drugs.

Area of Science:

  • Pharmacology
  • Neurology
  • Epileptology

Background:

  • Rufinamide is a novel antiepileptic drug with demonstrated effectiveness in various seizure models.
  • Its precise mechanism of action, potentially involving voltage-gated sodium channels, requires further elucidation.
  • Rufinamide presents a dosing schedule of twice daily with a notable interaction with oral contraceptives.

Purpose of the Study:

  • To evaluate the efficacy and safety of rufinamide as an antiepileptic treatment.
  • To investigate the pharmacokinetic profile, including the impact of food on absorption.
  • To assess the potential advantages of rufinamide compared to existing antiepileptic therapies.

Main Methods:

  • Assessment in acute animal seizure models and the kindling model of epilepsy.

Related Experiment Videos

  • Clinical trials evaluating rufinamide as adjunctive therapy.
  • Monitoring of adverse effects and cognitive profile.

    • Main Results:

    • Rufinamide shows high efficacy in animal models and as adjunctive therapy for partial epilepsy and Lennox-Gastaut syndrome.
    • Food significantly increases rufinamide absorption, potentially impacting clinical administration.
    • Minimal adverse effects were observed, including headache, dizziness, and fatigue, with a favorable cognitive profile.

    Conclusions:

    • Rufinamide is an effective antiepileptic drug with a generally favorable safety profile.
    • Its clinical utility may be influenced by food interactions affecting absorption.
    • Further clinical trials are necessary to determine rufinamide's comparative advantages in epilepsy management.